Report title: Agensys, Inc. (FKA: UroGenesys, Inc.) - Portfolio Company Report
from Thomson Financial Venture Economics
published Jun 20, 2009

Price $24.00 available for immediate download
Report Overview
 
About Thomson Financial Venture Econ...

Develops targeted cancer therapeutics based on antigen discoveries. The Company uses a variety of discovery and validation technologies to identify antigens with clinical relevance in multiple solid tumors and structural and functional characteristics amenable to multiple therapeutic modalities (antibody, vaccine, and small molecule). ; Develops targeted cancer therapeutics.

Report Type: This research report shows venture capital financing information for this specific company.
Executives Listed: 20
Number of Investing Funds: 16
Free Sample: Click Here to Download
Format:
PDF Adobe Acrobat


Price: $24.00



  Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.